Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol

Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvador, Fernando, Lucas-Dato, Ana, Roure, Silvia, Arsuaga, Marta, Pérez-Jacoiste, Asunción, García-Rodríguez, Magdalena, Pérez-Molina, José A., Buonfrate, Dora, Saugar, José María, Molina, Israel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308528/
https://www.ncbi.nlm.nih.gov/pubmed/34199000
http://dx.doi.org/10.3390/pathogens10070812
Descripción
Sumario:Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.

Ejemplares similares